Navigation Links
Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
Date:12/13/2007

Summary: Genmab has Announced Details of a Planned Phase II Study of

Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 receptor. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"Multiple sclerosis is a debilitating disease for which there are currently few treatments," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We hope our fully human antibody, ofatumumab, may offer another potential treatment option for patients suffering from this incapacitating disease."

About the trial

The double blind randomized trial will consist of two parts. Part A will include approximately 36 patients in one of three increasing dose cohorts (100 mg, 300 mg or 700 mg of ofatumumab) randomized to receive ofatumumab or placebo. An independent data monitoring committee (IDMC) will evaluate the safety of each sequential cohort prior to progression to the next cohort. When all patients in Part A have had their week 4 MRI scan, the IDMC will evaluate the data before Part B of the study begins.

Part B will consist of a 48 week treatment period of approximately 288 patients. Patients will be randomized to treatment with 100 mg, 300 mg, or 700 mg of ofatu
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Md. , July 22, 2014  United ... today that it will release its second quarter ... July 29, 2014. United Therapeutics will ... 2014, at 9:00 a.m. Eastern Time.  The teleconference ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will ...
(Date:7/22/2014)... Biofeedback – When a behavioral problem ... medication to best treat it can become a matter ... electroencephalography (EEG) can help predict which medicine will offer ... adverse drug events. , The article “Medication Prediction ... issue of the journal Biofeedback offers evidence that quantitative ...
(Date:7/21/2014)... Lawrence Livermore National Laboratory ... and Las Positas College (LPC) recently established a ... hands-on training for veterans, officials recently announced. , ... Positas is designed to help veterans develop ... careers, and establishes a pipeline of qualified candidates ...
(Date:7/21/2014)... Syracuse University,s College of Arts and Sciences has ... of stainless nanoparticles. , Mathew M. Maye, associate ... $360,000 grant from the National Science Foundation (NSF). ... stainless alloy nanostructures, the results of which may ... batteries. , Maye,s approach is novel, ...
Breaking Biology Technology:Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2
... Wisconsin Entrepreneurs Conference, held at the Hyatt Regency Milwaukee, ... on starting a company, learn how to improve revenue ... state. , ,However, at the conference luncheon on Tuesday, ... industry representatives by the guest speakers: inspiration. During ...
... roller-coaster ride of ups and downs during the past 15 ... worlds brightest scientists. They are tantalized by the enormous potential ... curing diseases of many kinds. , ,One group, consisting of ... the Waisman Center at UW-Madison and Mirus ...
... heard the drumbeat about IT project failure rates. Youve probably ... of sponsor support, poor requirements and scope definition, lack of ... apparent in all of this hand wringing is the real ... are technology based. For each one, the source is the ...
Cached Biology Technology:Celebrating Wisconsins entrepreneurial spirit 2Celebrating Wisconsins entrepreneurial spirit 3Researchers report major advance in gene therapy technique 2Researchers report major advance in gene therapy technique 3Researchers report major advance in gene therapy technique 4Analog people in the digital revolution 2Analog people in the digital revolution 3
(Date:7/22/2014)... habitats and trees and not just asphalt and recreation ... University of Colorado Boulder study. , Working on class ... benefits for youth, according to a paper published in ... is one of the first of its kind to ... settings and stress. , "Many schools already offer stress ...
(Date:7/22/2014)... lunch box and you,re likely to find that the lunches ... the findings of a study conducted by researchers at the ... and in the Department of Public Health and Community Medicine ... published online ahead of print in the Journal of ... by senior author Jeanne Goldberg, Ph.D., R.D., a professor at ...
(Date:7/22/2014)... , July 22, 2014 NXT-ID, Inc., (NXTD: ... m-commerce market, announces its next generation smart wallet, Wocket™, will ... oriented television show that airs on the History ... NewsWatch regularly features top technology products and ... on the History Channel (6:00-6:30am ET/PT) and the ...
Breaking Biology News(10 mins):Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3Room for improvement in elementary school children's lunches and snacks from home 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 2NXT-ID's Next Generation Wocket Smart Wallet to be Featured on NewsWatch, Airing on History Channel, FYI Network and ION Network 3
... Anthony D. Rosato, PhD, a professor in the department ... has received a Fulbright Senior Research Award ... particles at the University of Salerno, in Fisciano, Italy. ... Rosato recently presented an invited seminar there entitled "Microstructure ...
... The American Society for Biochemistry and Molecular Biology ... nonprofit,s annual awards. Another winner was announced earlier this ... society,s annual meeting April 9-13 in Washington, D.C., are ... Medical Institute investigator Axel T. Brunger won the inaugural ...
... ones making exciting scientific discoveries these days. Two middle ... who are reporting the first glimpse of the innermost ... certain antibiotics and anti-cancer agents so that those substances ... journal Biochemistry . The student co-authors of the ...
Cached Biology News:NJIT professor receives Fulbright to study at University of Salerno 2American Society for Biochemistry and Molecular Biology honors 11 outstanding scientists 2American Society for Biochemistry and Molecular Biology honors 11 outstanding scientists 3American Society for Biochemistry and Molecular Biology honors 11 outstanding scientists 4
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: